Michael Curtis
CEO
eGenesis, Inc.
The startup develops a gene editing and genome engineering platform that creates human-compatible organ tissue cells for solid organ and therapeutic cell transplantation. This technology aims to improve outcomes for patients with life-threatening diseases by enabling successful kidney and islet cell transplants.
- Biotechnology
Updated 15 days ago
Funding
Raised to date
$454MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
The demand for organs and cells significantly exceeds the available supply from human donors, leading to long waiting times, patient mortality, and suboptimal treatments for those with organ failure and other serious diseases. Traditional strategies to increase human organ donation have not been sufficient to close this gap.
Solution
eGenesis is developing Human Compatible (HuCo™) organs and cells using xenotransplantation to address the global transplant shortage. The company's EGEN™ platform leverages multiplex gene editing to modify porcine organs and cells, minimizing the risk of cross-species infection and immune-mediated rejection. By inactivating porcine endogenous retroviruses and introducing human genes, eGenesis aims to create organs and cells that are compatible with the human immune system, reducing the need for immunosuppression post-transplant. The company is initially focused on kidney and islet cell transplantation, with the goal of expanding to other solid organs.
Target Audience
The primary target audience includes patients with end-stage organ failure, transplant centers, and medical professionals seeking to expand the availability of organs and cells for transplantation.
Features
- Multiplex gene editing platform for precise and simultaneous genetic modifications
- Knockout of porcine genes that may trigger adverse immune responses in humans
- Insertion of human genes to enhance compatibility and reduce rejection
- Site-directed integration for controlled and verified genetic changes
- Biosecure, pathogen-free animal production processes to minimize the risk of viral transmission
- Clonal cell isolation to ensure genetic consistency
- Development of HuCo™ kidneys, islet cells, and livers